Today's breakout move in the stock is a highlight of the surging sector.
House Democrats start probe into MS drug prices
'Biogen has a relatively under-leverage balance sheet, and we expect [free cash flow yield] and US cash to grow.'
All eyes are on Pfizer in the months ahead.
©1996-2017 TheStreet, Inc. All rights reserved.Action Alerts PLUS is a registered trademark of TheStreet, Inc.